BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs3825942
,
DRD2
,
T cell receptor signaling pathway
,
HIV infection
,
Stem cell
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
Lag- 3
Summary
General Info
Curated Studies
Most Correlated Studies
CD4+ T regulatory and T helper cells stimulated with anti-CD3 and anti-CD28
Splenic CD8+ T cells treated with anti-CD4 antibody post immunization with Ad5HVR48-Gag virus
Embryonic stem cells HDAC1 and 2 double knockout - Timecourse
Osteosarcoma U-2 Os cell circadian gene expression in response to ARNTL knockdown
Fetal liver double negative cells plus double negative and positive thymocytes
Explore Curated Studies Results
Literature
Most Relevant Literature
LAG3 in gastric cancer: it's complicated.
Diminished LAG3+ B cells correlate with exacerbated rheumatoid arthritis.
Research progress of immune heckpoint LAG-3 in gastric cancer: a narrative review.
From bench to bedside: targeting lymphocyte activation gene 3 as a therapeutic strategy for autoimmu…
A combined analysis of multi-omics data reveals the prognostic values and immunotherapy response of …
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
PET Imaging of LAG-3 Expression
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Inject…
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ